JDQ443,tislelizumab
Novartis,Beigene
['kontrast-01', 'jdq443', 'sclc', 'nsclc']
ph1 study kontrast-01:
nice activity of jdq443 mono therapy in kras g12c nsclc
orr 57.1%
#asco2023 
Thoracic Medical Oncologist @BartsHospital, PhD in genomic medicine @Imperialcollege, Representative @ACPUK & @BTOGorg, @FMLM_UK clinical Fellow ‘18